glp-1 obesity drugs news today 2025 Alarming rise in weight loss drug overdoses Novo Nordisk cuts 2025 forecast
Description
The pharmaceutical industry currently has very few approved treatments for metabolic-associated steatotic liver disease
Saxenda has not been studied in patients with a history of pancreatitis
The results provide insights into the benefits and risks of GLP-1RAs and may be useful for informing clinical care and guiding research agendas
doi: 10.1210/clinem/dgae583 81 KroghLLNielsenCKBergmannNCHolstJJLundAGasbjergLSet al
106.Albiglutide SPC
